Aaron Cravens
Principal investigator, leads REVEL PHARMACEUTICALS INC..
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2023First federal award
$3.6MFederal grants as PI6 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
6 awards · $3.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 10, 2026 | NIH | SBIR Phase II Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts | $924K | REVEL PHARMACEUTICALS INC. |
| Aug 14, 2025 | NIH | SBIR Phase II Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts | $1.4M | REVEL PHARMACEUTICALS INC. |
| Jul 25, 2025 | NIH | SBIR Phase I Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy | $358K | REVEL PHARMACEUTICALS INC. |
| Jul 1, 2024 | NIH | SBIR Phase I An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts | $347K | REVEL PHARMACEUTICALS INC. |
| Apr 29, 2024 | NIH | SBIR Phase I Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease | $324K | REVEL PHARMACEUTICALS INC. |
| Aug 14, 2023 | NIH | SBIR Phase I Development of enzymatic tools for rapid measurement of Advanced Glycation End Product-protein adducts | $278K | REVEL PHARMACEUTICALS INC. |
Peer ranks
Federal funding#474
Awards as PI#315
Patents#273
Companies
- REVEL PHARMACEUTICALS INC.Leads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.